Melissa Lesko

Melissa Lesko

Auto-generated profile, based on publicly available information

Melissa Lesko

Transplant Institute, NYU Langone Health

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2024 in JHLT Open
Verified
Journal Article
Open access
SCStephanie H. Chang
Stephanie H. Chang
TGTravis C. Geraci
Travis C. Geraci
GPGreta L. Piper
Greta L. Piper
JCJustin Chan
Justin Chan
LJLes James
Les James
LALuis Angel
Luis Angel
Donation after circulatory death with thoracoabdominal normothermic regional perfusion (DCD-NRP) for cardiac transplant has promising results, though data for lung transplant is lacking. This study evaluates lung transplant outcomes using DCD-NRP allografts. All patients who underwent lung transplantation (LT) from June 1, 2020, to July 5, 2023, at a single institution were evaluated. Recipients received organs from DCD-NRP or brain dead (control) donors (donation after brain death (DBD)). All DCD-NRP were adult, primary bilateral LT (BLT) without preoperative extracorporeal membrane oxygenation (ECMO). Inclusion criteria for controls were age >18 years, BLT, no preoperative ECMO, and primary transplantation. Comparison was separated by LT or heart-lung transplant (HLT). The primary outcome was primary graft dysfunction (PGD) grade 3 at 72 hours. There were 8 LT and 3 HLT in the DCD-NRP cohort, and 138 BLT and 7 HL DBD controls. PGD grade 3 at 72 hours was 0% in the entire DCD-NRP cohort (vs control: 9.4% LT and 0% HLT). There were no statistically significant differences in donor and recipient characteristics, though DCD-NRP HLT had significantly shorter ischemic time (85 vs 200 minutes, p < 0.02). Thirty-day and 90-day mortality and 1-year survival are similar in both cohorts for LT and HLT. To date, DCD-NRP recipients are all on room air, with 0% acute cellular rejection rate and 91% (10/11) without chronic rejection. The lung utilization rate of evaluated DCD-NRP donors was 100%. Initial results of LT using DCD-NRP organs demonstrate similar PGD grade 3 at 72 hours and similar survival to standard donors.

1 April 2021 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
DRD. Rudym
D. Rudym
MLM. Lesko
M. Lesko
SCS. Chang
S. Chang
ZKZ. Kon
Z. Kon
KSK. Sureau
K. Sureau
LAL. Angel
L. Angel

20 September 2026 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DSDarren E. Stewart
Darren E. Stewart
PSPhilip M. Sommer
Philip M. Sommer
VDVictoria Davis
Victoria Davis
SCStephanie H. Chang
Stephanie H. Chang
JNJake G. Natalini
Jake G. Natalini
LALuis F. Angel
Luis F. Angel

24 May 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
DSDarren E. Stewart
Darren E. Stewart
JRJessica Moore Ruck
Jessica Moore Ruck
AMAllan B. Massie
Allan B. Massie
DSDorry Segev
Dorry Segev
MLMelissa B. Lesko
Melissa B. Lesko
JNJake G. Natalini
Jake G. Natalini
The benefits of bilateral lung transplantation (BLT) versus single lung transplantation (SLT) are still debated. One impediment to clinical recommendations is that BLT vs. SLT advantages may vary based on underlying disease. Since both options are clinically tenable in patients with emphysema, we conducted a comprehensive assessment of lung allograft survival in this population. Using U.S. registry data, we studied time to all-cause allograft failure in 8,092 patients 12 years or older transplanted from 2006 to 2022, adjusting for recipient, donor, and transplant factors by inverse propensity weighting. Median allograft survival was 6.6 years in BLT compared to 5.3 years in SLT, a 25% risk-adjusted survival advantage of 0.81.31.8 years. Risk-adjusted bilateral survival advantages varied between 0.9 and 2.4 years across eleven subgroups. Median allograft survival in BLT was 1.2 years greater than right SLT and 2.0 years greater than left SLT. During the 16-year study period, allograft survival steadily improved for BLT but not for SLT. Although the 25% BLT survival advantage pre-dated the pandemic, COVID-19 may have contributed to an apparent SLT survival decline. Recognizing the possible influence of residual confounding due to selection biases, these findings may aid offer decision-making when both donor lungs are available.

1 May 2023
Verified
Conference Paper
Closed access
PPP. Pamar
P. Pamar
KKK. Krolikowski
K. Krolikowski
DRD. Rudym
D. Rudym
MLM. Lesko
M. Lesko
LAL.F. Angel
L.F. Angel
JNJ.G. Natalini
J.G. Natalini

1 May 2023
Verified
Conference Paper
Closed access
NNN. Nelson
N. Nelson
KWK. Wong
K. Wong
TMT. Malik
T. Malik
DRD. Rudym
D. Rudym
MLM. Lesko
M. Lesko
JNJ.G. Natalini
J.G. Natalini